Multiple myeloma is diagnosed in over 100,000 patients each year worldwide, has an increasing incidence and prevalence in many regions, and follows a relapsing course, making it a significant and growing healthcare challenge. Recent basic, translational, and clinical studies have expanded our therapeutic armamentarium, which now consists of alkylating agents, corticosteroids, deacetylase inhibitors, immunomodulatory agents, monoclonal antibodies, and proteasome inhibitors. New drugs in these categories, and additional agents, including both small and large molecules, as well as cellular therapies, are under development that promise to further expand our capabilities and bring us closer to the cure of this plasma cell dyscrasia.

中文翻译：

---

多发性骨髓瘤的新药。

在世界范围内，每年全球有超过100,000名患者被诊断出多发性骨髓瘤，在许多地区其发病率和患病率均在上升，并且随着复发的进程而发展，这成为一项重大且日益严峻的医疗保健挑战。最近的基础，翻译和临床研究已经扩展了我们的治疗性武器库，该武器库现在由烷基化剂，皮质类固醇，脱乙酰基酶抑制剂，免疫调节剂，单克隆抗体和蛋白酶体抑制剂组成。这些类别的新药以及包括小分子和大分子在内的其他药物以及细胞疗法正在开发中，有望进一步扩大我们的能力，使我们更接近于治愈这种浆细胞性痢疾。